Beiersdorf Aktiengesellschaft (OTCMKTS:BDRFF) Receives Consensus Rating of “Reduce” from Analysts

Beiersdorf Aktiengesellschaft (OTCMKTS:BDRFF) has earned a consensus recommendation of “Reduce” from the six brokerages that are currently covering the company, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating and four have assigned a hold rating to the company.

A number of equities analysts have issued reports on BDRFF shares. Royal Bank Of Canada cut Beiersdorf Aktiengesellschaft from a “sector perform” rating to an “underperform” rating in a report on Tuesday, March 10th. UBS Group raised Beiersdorf Aktiengesellschaft from a “sell” rating to a “neutral” rating in a research report on Tuesday. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Beiersdorf Aktiengesellschaft in a report on Wednesday, March 18th. Morgan Stanley downgraded shares of Beiersdorf Aktiengesellschaft from an “equal weight” rating to an “underweight” rating in a research report on Monday, March 16th. Finally, Berenberg Bank restated a “hold” rating on shares of Beiersdorf Aktiengesellschaft in a research note on Monday, March 23rd.

Beiersdorf Aktiengesellschaft Stock Performance

BDRFF remained flat at $85.19 during trading on Tuesday. 16 shares of the company’s stock were exchanged, compared to its average volume of 5,727. The company’s 50 day moving average price is $105.48 and its two-hundred day moving average price is $106.90. Beiersdorf Aktiengesellschaft has a 1 year low of $83.94 and a 1 year high of $145.88.

Beiersdorf Aktiengesellschaft Company Profile

Beiersdorf Aktiengesellschaft is a global consumer goods company headquartered in Hamburg, Germany, with a history dating back to its founding in 1882 by pharmacist Paul C. Beiersdorf. The company is best known for its skincare brands, including NIVEA, Eucerin, La Prairie and Labello, as well as its tesa division, which produces self-adhesive products and industrial tapes. Over its long history, Beiersdorf has built a reputation for innovation in dermatological research and product development, introducing pioneering formulations that span mass-market and premium segments.

The company’s operations are organized into two main business divisions.